Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: NeOnc is a clinical-stage biopharmaceutical company focused on developing novel drug delivery methods and candidates for intracranial malignancies (brain cancers). The company's lead products are NEO100 (intranasal perillyl alcohol) and NEO212 (oral conjugate of perillyl alcohol and temozolomide). The company has no approved commercial products and generates minimal revenue from humanitarian "right to try" programs.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $39,990 | $83,000 |
| Net Loss | $(62,146,210) | $(11,898,464) |
| Operating Expenses | $58,280,435 | $7,225,522 |
| Research & Development | $3,638,257 | $3,045,239 |
| Cash and Cash Equivalents (Year End) | $58,729 | $64,893 |
| Accumulated Deficit | $(112,754,655) | $(50,608,445) |
| Convertible Debt (Net) | $5,952,066 | $0 |
Note: The 2025 Net Loss includes a significant non-cash charge of $35.6 million for share-based compensation and $11.8 million in advisory fees related to the company's direct listing.
Material Changes vs. Prior Period
- Listing Status: The company completed a direct listing on the Nasdaq Global Market under the symbol "NTHI" on March 25, 2025.
- Expense Surge: Total operating expenses increased by approximately $51 million year-over-year. This was primarily driven by the recognition of $35.6 million in share-based compensation (RSUs) and $11.8 million in advisory fees upon listing, which were not present in 2024.
- Debt Structure: The company issued $4.0 million in convertible promissory notes in July 2025 with an Original Issue Discount (OID). By year-end, the carrying value was approximately $5.95 million due to OID accretion. This debt was repaid in full in March 2026.
- Asset Acquisition: In October 2025, the company acquired a patent portfolio (U.S. Patent No. 11,788,057 B2) for $500,000, covering AI-driven drug discovery and 3D bioprinting technologies.
- Going Concern: The independent auditor issued a "going concern" opinion, citing substantial doubt about the company's ability to continue operations for the next twelve months without additional financing.
Guidance, Outlook, and Risks
Clinical Pipeline Progress
- NEO100: Phase IIa trials are ongoing for recurrent malignant glioma and meningioma. Preliminary data from combined cohorts showed 21% radiographic response and 44% six-month progression-free survival in IDH1-mutant patients. The company projects a Phase II readout by the end of 2024 (accelerated from 2025).
- NEO212: Phase I dose-escalation is complete. The Maximum Tolerated Dose (MTD) was reached, and the Recommended Phase 2 Dose (RP2D) was established at 610 mg. The company plans to engage the FDA for an End-of-Phase 1 meeting.
Outlook and Financing
The company expects to continue incurring significant losses as it advances clinical trials. It has raised approximately $16 million in a PIPE financing in early 2026 (subsequent to year-end) to settle outstanding obligations and fund operations. The company relies on equity offerings, debt financing, and potential collaborations to fund future operations.
Key Risks and Contingencies
- Liquidity Risk: As of December 31, 2025, cash on hand was only $58,729 against current liabilities of $20 million. The company faces substantial doubt regarding its ability to continue as a going concern.
- Legal Contingencies:
- Orient EuroPharma (OEP): A $4.0 million settlement liability exists regarding a terminated collaboration. The company disputes the timing of payment, but the liability is recorded on the balance sheet.
- Fox Infused: A settlement of approximately $738,000 (including interest) was outstanding at year-end but was paid in March 2026.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including segregation of duties, related party transactions, and IT user access management.
- Regulatory Risk: No products are approved. Success depends on clinical trial outcomes and FDA approvals, which are uncertain.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $16 million PIPE financing raised in early 2026 to cover operating expenses and debt obligations for the next 12-18 months.
- Debt Repayment: Confirm the full repayment of the $6.67 million convertible note and the $738k Fox Infused settlement in Q1 2026.
- Legal Liability: Monitor the status of the $4.0 million OEP litigation settlement and any potential additional legal costs.
- Clinical Milestones: Track the timeline for the NEO100 Phase II readout and the NEO212 Phase 2 initiation.
- Internal Controls: Review the remediation plan for the identified material weaknesses in financial reporting controls.
- Dilution: Assess the impact of recent and future equity issuances (PIPE, warrants, RSUs) on existing shareholder ownership.